Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$9.95 USD
+0.46 (4.85%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $10.00 +0.05 (0.50%) 9:08 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.95 USD
+0.46 (4.85%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $10.00 +0.05 (0.50%) 9:08 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
by Zacks Equity Research
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
by Zacks Equity Research
Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for January 11th (Revised)
by Zacks Equity Research
ADMA and ARQT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 11th
by Zacks Equity Research
ADMA, ARQT and PHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.
New Strong Buy Stocks for January 11th
by Zacks Equity Research
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
by Zacks Equity Research
Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
by Zacks Equity Research
The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT)
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Arcutis Biotherapeutics, Inc. (ARQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion
by Zacks Equity Research
Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up
by Zacks Equity Research
Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of 4.92% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.